CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Patients with relapsed/refractory multiple myeloma will be enrolled in a dose-escalation
phase receiving monotherapy CID-103. Once the recommended CID-103 dose and infusion duration
is known, additional patients will be enrolled in an expansion phase consisting of two
cohorts (anti-CD38 pretreated, and anti-CD38 treatment naïve). Patients will be treated until
disease progression or unacceptable toxicities.